In contrast, this updated review places a stronger emphasis on primary research articles, predominantly concerning ovarian cancer and predictive biomarkers for PARP inhibitors, as detailed in Table 2 for a comparative summary. This evidence concerns the gene PARP1 and ovarian cancer.